No registered clinical trials extracted for AHK-Cu yet. Off-label / exploratory data exists for 1 additional indication (Preclinical / mechanistic research).
Data last updated
Measured on 3 of 6 axes
Evidence shape
No registered clinical trials extracted for AHK-Cu yet. Off-label / exploratory data exists for 1 additional indication (Preclinical / mechanistic research).
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How AHK-Cu is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community users take AHK‑Cu subcutaneously once a day, typically around 1 mg (range 1–3 mg); a smaller subset follows unspecified schedules, using amounts up to 10 mg.